[Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
Treatment of anemia with human recombinant erythropoietin (EPO-R) and its effect on bone marrow was studied in 10 anemic patients on periodic hemodialysis (HD). Blood transfusion was not required once treatment started. Hemoglobin (Hb) levels normalized at six months in all patients (7.2 +/- 0.2 vs 12.4 +/- 3 g/dl, p less than 0.01). Serum ferritin levels decreased progressively as Hb increased (r = -0.5609), and six patients needed iron supplement since the third month. Bone marrow iron deposits decreased significantly (p less than 0.001), together with an increase of cellularity and improvement of erythrodysplasia. EPO-R was associated with worsening hypertension in previously hypertensive patients, although it could be controlled with more aggressive treatment. Thrombotic events either systemic or at the vascular access, were not observed. EPO-R corrects the anemia in uremic patients undergoing HD. Iron stores and blood pressure in hypertensive patients on treatment with EPO-R must be monitored regularly.
García Martín
F
F
Sección de Nefrología, Hospital Virgen de la Luz, Cuenca.
Carrascosa Vallejo
T
T
Martín Escobar
E
E
Val Begueria
J
J
Martín Hernández
R
R
de Arriba
G
G
Teno
C
C
Salvatierra
J
J
D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
D011994:Recombinant Proteins; D004921:Erythropoietin
Tratamiento de la anemia con eritropoyetina humana recombinante y respuesta medular en pacientes urémicos en hemodiálisis periódicas.